BACKGROUND:African Americans have higher tobacco-related morbidity and mortality and are more likely to smoke menthol cigarettes than their white counterparts. This study examined differences between African American menthol and non-menthol smokers in smoking characteristics and cessation. METHODS: The study sample consisted of 600 African American smokers enrolled in a clinical trial that assessed the efficacy of sustained-release bupropion for smoking cessation. Menthol (n = 471) and non-menthol (n = 129) smokers were compared on smoking-related characteristics and abstinence rates at 6 weeks and 6 months. RESULTS:Menthol smokers were younger (41.2 versus 52.9 years), more likely to be female (73.7% versus 56.6%) and more likely to smoke their first cigarette within 30 minutes of waking up (81.7% versus 69.8%) compared to non-menthol smokers (all P < 0.01). Cigarette taste (50% versus 40%, P = 0.054) was rated non-significantly higher by menthol smokers. Seven-day point-prevalence abstinence from smoking at 6 weeks were 28% and 42% (P = 0.006) and at 6 months were 21% and 27% (P = 0.21) for menthol and non-menthol smokers, respectively. At 6 weeks follow-up, stepwise logistic regression revealed that among those younger than 50 years, non-menthol smokers were more likely to quit smoking (odds ratio = 2.0; 95% CI = 1.03-3.95) as were those who received bupropion (odds ratio = 2.12; 95% CI = 1.32-3.39). CONCLUSION:African American menthol smokers had lower smoking cessation rates after 6 weeks of treatment with bupropion-SR, thereby putting menthol smokers at greater risk from the health effects of smoking. Lower overall cessation rates among African Americansmenthol smokers may partially explain ethnic differences in smoking-related disease risks.
RCT Entities:
BACKGROUND: African Americans have higher tobacco-related morbidity and mortality and are more likely to smoke menthol cigarettes than their white counterparts. This study examined differences between African American menthol and non-menthol smokers in smoking characteristics and cessation. METHODS: The study sample consisted of 600 African American smokers enrolled in a clinical trial that assessed the efficacy of sustained-release bupropion for smoking cessation. Menthol (n = 471) and non-menthol (n = 129) smokers were compared on smoking-related characteristics and abstinence rates at 6 weeks and 6 months. RESULTS:Menthol smokers were younger (41.2 versus 52.9 years), more likely to be female (73.7% versus 56.6%) and more likely to smoke their first cigarette within 30 minutes of waking up (81.7% versus 69.8%) compared to non-menthol smokers (all P < 0.01). Cigarette taste (50% versus 40%, P = 0.054) was rated non-significantly higher by menthol smokers. Seven-day point-prevalence abstinence from smoking at 6 weeks were 28% and 42% (P = 0.006) and at 6 months were 21% and 27% (P = 0.21) for menthol and non-menthol smokers, respectively. At 6 weeks follow-up, stepwise logistic regression revealed that among those younger than 50 years, non-menthol smokers were more likely to quit smoking (odds ratio = 2.0; 95% CI = 1.03-3.95) as were those who received bupropion (odds ratio = 2.12; 95% CI = 1.32-3.39). CONCLUSION: African American menthol smokers had lower smoking cessation rates after 6 weeks of treatment with bupropion-SR, thereby putting menthol smokers at greater risk from the health effects of smoking. Lower overall cessation rates among African Americans menthol smokers may partially explain ethnic differences in smoking-related disease risks.
Authors: Kolawole S Okuyemi; Babalola Faseru; Gregory A Reed; Lisa Sanderson Cox; Carrie A Bronars; Isaac Opole; Guy-Lucien Whembolua; Matthew S Mayo; Jasjit S Ahluwalia; Neal L Benowitz Journal: Nicotine Tob Res Date: 2012-02-08 Impact factor: 4.244
Authors: Karen L Cropsey; Michael F Weaver; Gloria D Eldridge; Gabriela C Villalobos; Al M Best; Maxine L Stitzer Journal: Nicotine Tob Res Date: 2009-04-22 Impact factor: 4.244
Authors: Babalola Faseru; Won S Choi; Ron Krebill; Matthew S Mayo; Nicole L Nollen; Kolawole S Okuyemi; Jasjit S Ahluwalia; Lisa Sanderson Cox Journal: Addict Behav Date: 2011-07-22 Impact factor: 3.913
Authors: David T Levy; Jennifer L Pearson; Andrea C Villanti; Kenneth Blackman; Donna M Vallone; Raymond S Niaura; David B Abrams Journal: Am J Public Health Date: 2011-05-12 Impact factor: 9.308
Authors: Philip H Smith; Biruktawit Assefa; Simranpreet Kainth; Kaliris Y Salas-Ramirez; Sherry A McKee; Gary A Giovino Journal: Nicotine Tob Res Date: 2020-03-16 Impact factor: 4.244
Authors: Babalola Faseru; Nicole L Nollen; Matthew S Mayo; Ron Krebill; Won S Choi; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia; Lisa Sanderson Cox Journal: Addict Behav Date: 2012-11-29 Impact factor: 3.913
Authors: Miranda R Jones; Benjamin J Apelberg; Maria Tellez-Plaza; Jonathan M Samet; Ana Navas-Acien Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-12-18 Impact factor: 4.254
Authors: Babalola Faseru; Lisa S Cox; Carrie A Bronars; Isaac Opole; Gregory A Reed; Matthew S Mayo; Jasjit S Ahluwalia; Kolawole S Okuyemi Journal: BMC Med Res Methodol Date: 2010-01-19 Impact factor: 4.615